Dominic Xavier salutes every single person involved in making this miracle possible.
The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals. The Pune-based Serum Institute of India, the world's largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, 'Covishield', for state governments and Rs 600 per dose for private hospitals.
Confirming the Drugs Controller General Of India (DCGI) approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted: '@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly.'
According to the sources, the vaccine will be much more affordable than existing ones manufactured by two foreign companies. India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm.
The Serum Institute of India (SII) had put in an application to the Drugs Controller General of India (DCGI) in October for grant of market authorisation of Covovax for restricted use in emergency situations.
Alleging that the candidate vaccine was not safe, he has also sought cancelling approval for its testing, 'manufacture and distribution', failing which legal action would be taken.
This year, eight eminent individuals are being given Padma Bhushan and 54 are being conferred with Padma Shri awards, besides the two Padma Vibhushan recipents.
A source closely involved in logistical arrangements said the movement of vaccine doses is likely to start from early Tuesday morning through road and air routes amid elaborate police security.
No decision on granting indemnity to any foreign or Indian Covid vaccine-manufactures has been taken yet, the government said Friday, underlining these decisions are to be taken 'in the interest of nation and people'.
The study also noted that the booster dosage of the company's COVID-19 vaccine Vaxzevria also increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
A bench of Justices L Nageswara Rao and B R Gavai said bodily autonomy and integrity are protected under Article 21 of the Constitution.
The Serum Institute of India has informed the Centre that it will be able to supply around 22 crore doses of Covishield in October as the Union government has announced resuming export of surplus Covid vaccines in the coming fourth quarter under the 'Vaccine Maitri' programme, official sources said.
Apollo Hospitals and Fortis Healthcare are open to importing vaccines.
Poonawalla said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.
Earlier this month, India had said that all British nationals arriving in India from the UK will have to undergo a mandatory 10-day quarantine if they are fully vaccinated against COVID-19.
'Supplies should start moving to the Serum Institute without any impediments.'
Addressing a press briefing, Union Health Secretary Rajesh Bhushan said vaccine effectiveness will be seen only after 14 days.
CEO of Serum Institute of India hints that he may start producing in Britain and speaks about threatening calls from the rich and powerful
In a recent letter to Union Home Minister Amit Shah, SII said its employees have been working round the clock in spite of various challenges because of the pandemic.
Apart from the 1.1 crore doses of Covishield being procured from the Serum Institute of India, 55 lakh doses of indigenously developed Covaxin were being obtained from Bharat Biotech, Union Health Secretary Rajesh Bhushan said at a press conference.
Microsoft Chairman and CEO Satya Nadella along with Alphabet Inc and its subsidiary Google CEO Sundararajan Pichai are also among those from trade and industry who have been awarded the Padma Bhushan for their distinguished services.
We are entering 2022, facing another infectious variant, with much the same baseless confidence, notes Mihir S Sharma.
Best celeb outfits from the Coachella Valley Music and Arts Festival.
An expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data for COVID-19 vaccine candidates of Serum Institute and Bharat Biotech, after deliberating upon their applications seeking emergency use authorisation for the shots, official sources said.
"I realise that a lot of Indians who have taken Covishield are facing issues with travel to the EU, I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said in a tweet.
On production capacity of Covishield, the vaccine being manufactured and supplied by Serum in India under a licensing agreement with Oxford and AstraZeneca, he said the present capacity is 130 million doses per month and always try to increase it further.
Pune-based entrepreneur's unlisted company is already the largest vaccine manufacturer in the world and the networth has been helped by vaccine distribution and manufacturing potential of his business, it added. Recentrly, Serum struck an agreement with AstraZeneca to manufacture 1 billion doses of coronavirus vaccine being developed by Oxford University.
Recalling how the industry used to face "hardships" in securing permissions and "harassment from bureaucrats" 50 years ago, chairman of the Pune-based vaccine maker Serum Institute of India (SII), Dr Cyrus Poonawalla, on Friday hailed the Modi government saying that red-tapism and licence raj have come down under its rule.
Serum Institute of India CEO Aadar Poonawalla has said that the production of Covid-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country in a few days. Poonawalla is currently in the UK to meet his family members.
Reliance Industries chairman Mukesh Ambani and his wife Nita Ambani topped a list of power couples dominated by celebrity pairs from Bollywood, according to the annual survey results released by the Indian Institute of Human Brands (IIHB) in Mumbai on Wednesday. Ranveer Singh and Deepika Padukone followed the Ambanis at No 2, and Virat Kohli and Anushka Sharma occupied the third position. Five other couples from the corporate world made it to the list - Infosys founder Narayana Murthy and Sudha Murty at 10th, Adar and Natasha Poonawala (Serum Institute) at 11th, Azim and Yasmeen Premji (Wipro) at 16th, Anand and Anuradha Mahindra (Mahindra Group) at 19th, and Kumar Mangalam and Neerja Birla (Aditya Birla Group) at 20th position.
Modi on Saturday will embark on a three-city tour to take stock of the COVID-19 vaccine development work.
India will be within its rights to initiate reciprocal measures if the UK does not address concerns over the new travel rules relating to COVID-19 vaccine certification, foreign secretary Harsh Vardhan Shringla said on Tuesday describing the policy as "discriminatory".
Dominic Xavier ponders the Vaccine Dilemma: Should he take the shot or not?
The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.
This is Kareena's first appearance after she gave birth to her second son on February 21.
The company has set an affordable ceiling price of USD 3 (around Rs 225) per dose, it added.
Ahmedabad was the first stop in the PM's three city tour today, to personally review the vaccine development and manufacturing process in the country.
This will be Modi's first interaction with chief ministers following the recent approval of two coronavirus vaccines for restricted emergency use by India's drug regulator.
While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.
Two weeks after the vaccination programme started, about 37 per cent of the targeted 10 million healthcare professionals had received the first shot. This slow rate may prompt the government to allow vaccines in the private market sooner, to use up the doses before they expire, Sohini Das reports.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances